The 9th "International Symposium on Current Trends in Drug Discovery Research” inaugurated yesterday at CSIR-Central Drug Research Institute, Lucknow. Dr. Radha Rangrajan, Director CSIR-CDRI, Lucknow, ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...

The FDA has granted Fast Track designation to PP-01 for the mitigation of cannabis withdrawal symptoms in patients with cannabis use disorder.

Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that it costs $100 to $300 million to develop a biosimilar and that it takes ...

The approval makes Vraylar (cariprazine) the " first and only" dopamine and serotonin partial agonist indicated as ... After a slow start, the drug has emerged as the star of AbbVie's $63 billion ...

A noteworthy case study. What caused a 43-year-old woman to develop lesions all over her body that were not only extremely ...

In a Phase III trial, 28 percent of newly diagnosed patients with H3 K27M-mutant diffuse glioma responded to treatment with dordaviprone.

Some studies link GLP-1 drugs for diabetes with neuroprotective benefits but others say that some of these drugs may increase ...

Epigenetic inhibitors as a promising new antimalarial intervention strategy? A new study identifies an inhibitor of gene regulation that specifically kills the malaria pathogen.